Skip to content
Clinical Trials – home

GSKVX000000077507: an investigational influenza vaccine

3 / 3
trials open to patients / all trials
4+
Countries

In short

GSKVX000000077507 is an investigational substance being studied as part of an influenza vaccine. It appears in two authorised Phase 3 trials in adults, with a combined reported enrollment of 57,000 participants. The trials compare the vaccine containing this substance against already authorised influenza vaccines.

Key points

  • GSKVX000000077507 is an investigational substance included in a vaccine being tested against influenza.
  • Both registered trials are Phase 3 studies in adults.
  • The larger trial enrolled 54,000 adults aged 65 years and older.
  • The smaller trial enrolled 3,000 adults aged 18 to 64 years.
  • Both trials are currently authorised in the EU registry.
  • The studies compare the investigational vaccine with Efluelda TIV-HD and other licensed influenza vaccines.

What is GSKVX000000077507?

GSKVX000000077507 is an investigational substance that appears as one component in a vaccine being studied against influenza. The full name GSKVX000000077507 is used once here; the short label GSKVX000000077507 identifies the substance in the trial records. The registry data do not state whether GSKVX000000077507 is a chemical or a protein-based substance, and no marketing authorisation is recorded for it in these trials.

How does GSKVX000000077507 work?

The trial records do not describe a mechanism of action for GSKVX000000077507 on its own. The substance is listed together with five other investigational codes — GSKVX000000077430, GSKVX000000077508, GSKVX000000077506, GSKVX000000077510 and GSKVX000000077509 — as one combined study intervention given by intramuscular injection. The studies aim to show that this investigational intervention is not inferior to already authorised influenza vaccines in preventing laboratory-confirmed influenza-like illness.

Which conditions is GSKVX000000077507 studied for?

  • Influenza, Human — both registered trials study the investigational vaccine in human influenza, the respiratory infection caused by influenza viruses.

How is GSKVX000000077507 given?

In both trials, the study intervention containing GSKVX000000077507 is given as a 0.5 ml dose by intramuscular use, meaning an injection into a muscle. The records do not state the pharmaceutical form beyond the volume and route.

What do the clinical trials show?

Two trials are registered for GSKVX000000077507, both in Phase 3 and both currently authorised in the EU Clinical Trials Information System. The larger trial, 2026-526682-14-00, enrolled 54,000 adults aged 65 years and older. The smaller trial, 2026-526925-17-00, enrolled 3,000 adults aged 18 to 64 years.

What are the trials measuring?

The larger trial measures the first occurrence, at least 14 days after dosing, of laboratory-confirmed cases of protocol-defined influenza-like illness caused by influenza A subtypes H1N1 or H3N2 or influenza B/Victoria. It also records solicited administration site and systemic events during the 7 days after dosing, unsolicited adverse events during the 28 days after dosing, and serious adverse events and adverse events of special interest up to the end of the corresponding influenza season with at least 180 days of follow-up.

The smaller trial measures haemagglutination inhibition titers and neuraminidase inhibition titers at Day 29, haemagglutination inhibition seroconversion from baseline to Day 29, solicited adverse events during the 7 days after dosing, unsolicited adverse events during the 28 days after dosing, and serious adverse events and adverse events of special interest up to 6 months after dosing.

Who can take part in these trials?

The larger trial is for adults aged 65 years and older. The smaller trial is for adults aged 18 to 64 years. Both trials are interventional studies, meaning participants receive a study intervention and are then followed over time.

What side effects are known?

The registry records do not report side effects for GSKVX000000077507. The trials are designed to collect information on solicited administration site and systemic events, unsolicited adverse events, serious adverse events and adverse events of special interest, but no results are reported in the registry data.

Questions people often ask

Conditions where GSKVX000000077507 is being studied

Each condition opens its own overview and trial list

Trials with GSKVX000000077507

Recruiting trials first

See all 3 →
Quick filters
  • Participants:Healthy volunteers
  • Participants:Adults · Healthy volunteers
  • Participants:Adults · Healthy volunteers
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.